Management of macular edema from branch retinal vein occlusions

References

• Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch. Ophthalmol. 100, 1132–1140 (1982).
   PubMedGoogle Scholar
• Coscas G, Loewenstein A, Augustin A et al. Management of retinal vein occlusion--consensus document. Ophthalmologica 226(1), 4–28 (2011).
   PubMed Web of Science ®Google Scholar
• Rogers S, McIntosh RL, Cheung N et al.; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117, 313–319 (2010).
   PubMed Web of Science ®Google Scholar
• Coscas G, Dhermy P. Occlusions veineuses rétiniennes. Masson, Paris, 283–346 (1978).
   Google Scholar
• Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmol. 98, 271–282 (1984).
   PubMed Web of Science ®Google Scholar
• Rogers SL, McIntosh RL, Lim L et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117, 1094–1101e5 (2010).
   PubMed Web of Science ®Google Scholar
• Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans. Am. Acad. Ophthalmol. Otolaryngol. 78, 166–177 (1974).
   Google Scholar
• Hayreh SS, Zimmerman M, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am. J. Ophthalmol. 117, 429–441 (1994).
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am. J. Ophthalmol. 131, 61–77 (2001).
   PubMed Web of Science ®Google Scholar
• Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology 99, 509–514 (1992).
   PubMed Web of Science ®Google Scholar
• Hirota A, Mishima HK, Kiuchi Y. Incidence of retinal vein occlusion at the Glaucoma Clinic of Hiroshima University. Ophthalmologica 211, 288–291 (1997).
   PubMed Web of Science ®Google Scholar
• Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb. Haemost. 93(6),1021–1026 (2005).
   PubMed Web of Science ®Google Scholar
• Rehak M, Rehak J, Müller M et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb. Haemost. 99(5), 925–929 (2008).
   PubMedGoogle Scholar
• Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am. J. Ophthalmol. 116, 286–296 (1993).
   PubMed Web of Science ®Google Scholar
• Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 106, 2054–2062 (1999).
   PubMed Web of Science ®Google Scholar
• Kirwan JF, Tsaloumas MD, Vinall H, Prior P, Kritzinger EE, Dodson PM. Sex hormone preparations and retinal vein occlusion. Eye (Lond) 11, 53–56 (1997).
   PubMed Web of Science ®Google Scholar
• Ciardella AP, Yannuzzi LA, Freund KB et al. Factor V Leiden, activated protein C resistance, and retinal vein occlusion. Retina 18, 308–315 (1998).
   PubMedGoogle Scholar
• Cruciani F, Moramarco A, Curto T et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risk factors for youth retinal vein occlusion. Clin. Ter. 154, 299–303 (2003).
   PubMedGoogle Scholar
• Glacet-Bernard A, les Jardins GL, Lasry S et al. Obstructive sleep apnea among patients with retinal vein occlusion. Arch. Ophthalmol. 128, 1533–1538 (2010).
   PubMedGoogle Scholar
• La Spina C, De Benedetto U, Battaglia Parodi M, Coscas G, Bandello F: Practical management of retinal vein occlusions. Ophthalmol. Ther. 1, 3 (2012).
   PubMedGoogle Scholar
• Ip MS, Scott IU, VanVeldhuisen PC et al.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care versus corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch. Ophthalmol. 127,1101–1114 (2009).
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117, 1134–1146 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am. J. Ophthalmol. 144, 864–871 (2007).
   PubMed Web of Science ®Google Scholar
• Figueroa MS, Contreras I, Noval S, Arruabarrena C: Results of bevacizumab as the primary treatment for retinal vein occlusion. Br. J. Ophthalmol. 94, 1052–1056 (2010).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117,1102–1112 (2010).
   PubMed Web of Science ®Google Scholar
• Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119(4), 802–809 (2012).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 120(4), 795–802 (2013).
   PubMed Web of Science ®Google Scholar
• Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusion of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 120(5), 1057–1063 (2013).
   PubMedGoogle Scholar
• Tsui I, Pan CK, Rahimy E, Schwartz SD. Ocriplasmin for vitreoretinal diseases. J. Biomed. Biotechnol. 2012, 354979 (2012).
   PubMedGoogle Scholar